| Han, Yaling |
NCT03287167: Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease |
|
|
| Recruiting | 4 | 1720 | RoW | 1 month DAPT, 6 months DAPT | Shanghai MicroPort Medical (Group) Co., Ltd. | Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy | 07/21 | 07/23 | | |
| Active, not recruiting | 3 | 428 | RoW | MiStent, TIVOLI | Micell Technologies, Hefei Life Science Medical Instruments Co. Ltd., Giant Med-Pharma Services Inc., CCRF Consulting Co., Ltd. | Coronary Heart Disease | 11/18 | 11/22 | | |
NCT04781114: The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia |
|
|
| Completed | 3 | 806 | RoW | JS002, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Hyperlipemia | 05/22 | 01/23 | | |
VCP1-III-01, NCT06577519: Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) |
|
|
| Recruiting | 3 | 1000 | RoW | Vicagrel, Clopidogrel | Jiangsu vcare pharmaceutical technology co., LTD | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | 12/26 | 12/26 | | |
PADN-HF-PH, NCT05824923: A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure |
|
|
| Recruiting | 3 | 264 | RoW | Pulmonary arterial denervation, PADN, Guideline-directed medical therapy (GDMT) for heart failure, GDMT medication for heart failure | Pulnovo Medical (Wuxi) Co., Ltd., The General Hospital of Northern Theater Command, The First Affiliated Hospital with Nanjing Medical University, First Hospital of Tsinghua University, Cangzhou Central Hospital, Fuwai Central China Cardiovascular Hospital, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Shanxi Cardiovascular Hospital, RenJi Hospital, Shanghai 10th People's Hospital, Beijing Anzhen Hospital, West China Hospital, Sichuan Academy of Medical Sciences, The First Affiliated Hospital of Soochow University, TEDA International Cardiovascular Hospital, Tianjin Medical University General Hospital, Renmin Hospital of Wuhan University, Zhongnan Hospital of Wuhan University, First Affiliated Hospital Xi'an Jiaotong University, Xiamen Cardiovascular Hospital, Xiamen University, Zhejiang University, Shengjing Hospital, First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital of Wenzhou Medical University, Gansu Provincial Hospital, Yanan Hospital of Kunming City, First Affiliated Hospital of Chongqing Medical University, Huaihe Hospital of Henan University, Zhengzhou Cardiovascular Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Nanchang University, Hunan Provincial People's Hospital, Tianjin Medical University Second Hospital, First Affiliated Hospital, Sun Yat-Sen University, The First Hospital of Jilin University | Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction | 08/25 | 02/27 | | |
NCT06339021: OCT or Angiography Guided De-escalation of DAPT |
|
|
| Not yet recruiting | 1 | 80 | RoW | OCT-guided PCI, Conventional angiography-based PCI, DAPT de-escalation, default DAPT regimen | Shenyang Northern Hospital | Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation, Neointimal Coverage, ST Elevation Myocardial Infarction | 12/26 | 12/26 | | |
NCT03040934: Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s) |
|
|
| Active, not recruiting | N/A | 196 | RoW | Firehawk sirolimus target eluting coronary stent system, Firehawk™, XIENCE Everolimus-Eluting Coronary Stent System, XIENCE EES | Shanghai MicroPort Medical (Group) Co., Ltd. | Drug-Eluting Stents, Percutaneous Coronary Intervention, Tomography, Optical Coherence | 09/19 | 10/23 | | |
NCT04569669: The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis |
|
|
| Not yet recruiting | N/A | 325 | RoW | FFR and FFRCT | CCRF Inc., Beijing, China, Shengshi Technology, Co., Ltd, Hangzhou, China | Coronary Stenosis | 10/21 | 03/22 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
BRIGHT-4, NCT03822975: Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI |
|
|
| Active, not recruiting | N/A | 6016 | RoW | Bivalirudin, unfractionated Heparin | Shenyang Northern Hospital | ST Elevation Myocardial Infarction | 05/22 | 05/23 | | |
| Recruiting | N/A | 20 | RoW | SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System | Shanghai Shenqi Medical Technology Co., Ltd | Mitral Regurgitation | 10/22 | 10/26 | | |
NCT05375110: NoYA RAISE Trial II (Radiofrequency Ablation-Based Interatrial Shunt for Heart Failure) |
|
|
| Recruiting | N/A | 120 | RoW | NoYAâ„¢ Radiofrequency Interatrial Shunt System | Hangzhou NOYA MedTech Co. Ltm. | Heart Failure | 12/22 | 12/23 | | |
NCT05015712: Effects of MICT on Cardiopulmonary Function in Patients After TAVI |
|
|
| Recruiting | N/A | 66 | RoW | moderate intensity continuous training | Han Yaling, MD | Valve Disease, Aortic, Cardiac Rehabilitation | 06/23 | 06/23 | | |
NCT05988450: Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation |
|
|
| Active, not recruiting | N/A | 125 | RoW | SQ-Kyrin Transcatheter Mitral Valve Repair System | Shanghai Shenqi Medical Technology Co., Ltd | Functional Mitral Regurgitation | 12/23 | 12/27 | | |
| Not yet recruiting | N/A | 3490 | RoW | standard DAPT, OPT-CAD score guided DAPT de-escalation | Shenyang Northern Hospital | Acute Coronary Syndrome | 12/25 | 12/25 | | |
| Not yet recruiting | N/A | 10000 | RoW | | Shenyang Northern Hospital | Coronary Heart Disease (CHD) | 10/26 | 10/30 | | |
NCT06357026: Phitys I™ Percutaneous Left Ventricular Assist System Study |
|
|
| Not yet recruiting | N/A | 344 | RoW | Percutaneous Ventricular Assist System（Phigine Medical）, intra-aortic balloon pump (IABP) | Shanghai NewMed Medical Co., Ltd., Shanghai Phigine Medical Technology Co., Ltd. | Coronary Artery Disease | 05/25 | 04/26 | | |
NCT05864456: Prizvalve Pro™ Transcatheter Aortic Valve Replacement Study |
|
|
| Recruiting | N/A | 73 | RoW | Prizvalve Pro™ transcatheter aortic valve system | Shanghai NewMed Medical Co., Ltd., The General Hospital of Northern Theater Command, West China Hospital | Aortic Valve Stenosis | 06/24 | 05/28 | | |
| Recruiting | N/A | 3600 | RoW | SGLT-2 inhibitors | Shenyang Northern Hospital | Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy | 12/24 | 12/24 | | |
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) |
|
|
| Recruiting | N/A | 116 | RoW | TaurusTrio™ Heart Valve System | Peijia Medical Technology (Suzhou) Co., Ltd. | Aortic Regurgitation | 07/24 | 07/29 | | |
| Not yet recruiting | N/A | 10 | RoW | DragonFire Transcatheter Myocardial Radiofrequency Ablation System | Hangzhou Valgen Medtech Co., Ltd | Obstructive Hypertrophic Cardiomyopathy | 06/25 | 06/26 | | |
NCT06639321: Phimume® Percutaneous Left Ventricular Assist System Study |
|
|
| Not yet recruiting | N/A | 250 | RoW | Percutaneous Ventricular Assist System, extracorporeal membrane oxygenation (ECMO) | Shanghai NewMed Medical Co., Ltd., Shanghai Phigine Medical Technology Co., Ltd. | Coronary Artery Disease | 11/25 | 10/26 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
CRUISE-CTO, NCT04944615: To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease. |
|
|
| Recruiting | N/A | 1448 | RoW | The guidewire successfully passed the CTO lesion, Load dose administration | CCRF Inc., Beijing, China, BSC International Medical Trading (Shanghai) Co., Ltd. | Chronic Total Occlusion of Coronary Artery | 10/31 | 10/31 | | |
| Not yet recruiting | N/A | 1029 | RoW | clonal hematopoiesis of indeterminate potential | Shenyang Northern Hospital | ACS, Clonal Hematopoiesis of Indeterminate Potential, Smoking Cessation | 08/23 | 08/24 | | |
| Li, Yan |
NCT04035824: Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study |
|
|
| Completed | 4 | 605 | RoW | Gastrodia and Uncaria granule, Placebo of Gastrodia and Uncaria granule | Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Hypertension | 04/24 | 04/24 | | |
NCT05089448: Morning Versus Bedtime Dosing of Antihypertensive Medication |
|
|
| Recruiting | 4 | 300 | RoW | Alisartan, Amlodipine besylate | Yan Li | Hypertension, Blood Pressure, Drug Use | 06/26 | 09/26 | | |
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule |
|
|
| Recruiting | 4 | 480 | RoW | Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Functional Dyspepsia, Postprandial Distress Syndrome | 12/23 | 12/23 | | |
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT04078568: Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease |
|
|
| Active, not recruiting | 3 | 3208 | RoW | IVIG, Intravenous Immunoglobulins, Human, Aspirin, Acetylsalicylic acid, Prednisolone, STEROLONE | Children's Hospital of Fudan University, Jiangxi Province Children's Hospital, First People's Hospital of Hangzhou, Shengjing Hospital, The First Hospital of Jilin University, Chengdu Women's and Children's Central Hospital, Children's Hospital of Chongqing Medical University, Inner Mongolia People's Hospital, Sichuan Provincial People's Hospital, Wuhan Union Hospital, China, Third Affiliated Hospital of Zhengzhou University, Children's Hospital of Soochow University, Yuying Children's Hospital of Wenzhou Medical University, Beijing Children's Hospital, Qilu Hospital of Shandong University | Kawasaki Disease | 12/24 | 12/25 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa |
|
|
| Recruiting | 3 | 1680 | RoW | Tranexamic acid, 0.9% sodium chloride | Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital | Hemorrhage, Postpartum, Placenta Previa | 02/25 | 04/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
NCT04405154: A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer |
|
|
| Not yet recruiting | 2 | 32 | NA | Camrelizumab, SHR-1210, Cisplatin, Platinol, IMRT or VMAT | West China Hospital | Head and Neck Neoplasms | 05/23 | 05/25 | | |
NCT05299697: A Study of TG103 Injection in Overweight or Obesity |
|
|
| Recruiting | 2 | 195 | RoW | TG103 15 mg, TG103 22.5 mg, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Overweight or Obesity | 06/23 | 09/23 | | |
NCT06206720: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV |
|
|
| Recruiting | 2 | 60 | RoW | Deuremidevir Hydrobromide for Suspension, VV116, Placebo, VV116 placebo | Vigonvita Life Sciences | Respiratory Syncytial Virus Infection | 01/25 | 01/25 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
| Active, not recruiting | 2 | 103 | Europe, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627 | Novartis Pharmaceuticals | IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy | 07/24 | 07/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN |
|
|
| Recruiting | 2 | 60 | RoW | PM8002, FOLFIRI | Biotheus Inc. | Neuroendocrine Neoplasm | 01/27 | 01/28 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
NCT05056389: Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) |
|
|
| Recruiting | 1 | 20 | Europe | Oxaliplatin, Intraperitoneal catheter | Oslo University Hospital | Peritoneal Metastases, Colo-rectal Cancer | 03/23 | 06/23 | | |
| Recruiting | 1 | 76 | RoW | HS-10380, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Schizophrenia | 06/23 | 07/23 | | |
NCT06594315: Assessing Brain Metabolism Using MRS With Deuterated Glucose |
|
|
| Active, not recruiting | N/A | 80 | US | Deuterated Glucose, Hydrogen gas (H2) glucose, [6,6'-2H2] glucose, Magnetic Resonance Imaging (MRI), MRI, Blood Sample, MR spectroscopy (MRS), MRS | University of California, San Francisco | Glioma | 07/27 | 07/27 | | |
NCT06610604: Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules |
|
|
| Recruiting | N/A | 500 | RoW | thermal ablation, thyroidectomy | Ming-an Yu | Thyroid Nodule | 06/27 | 12/27 | | |
NCT05258461: An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy |
|
|
| Not yet recruiting | N/A | 108 | NA | use of a smartphone app for adverse event management, conventional adverse event management | Peking Union Medical College Hospital | Breast Cancer | 10/22 | 12/22 | | |
NCT03547856: A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients" |
|
|
| Recruiting | N/A | 10000 | RoW | | Yan Li | Hypertension, Blood Pressure, Cardiovascular Diseases | 09/26 | 12/26 | | |
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events |
|
|
| Recruiting | N/A | 100000 | RoW | | Chinese Academy of Medical Sciences, Fuwai Hospital | Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment | 12/22 | 12/23 | | |
| Recruiting | N/A | 4500 | RoW | | Shanghai Institute of Hypertension | Nocturnal Hypertension | 09/26 | 12/26 | | |
PROMISE, NCT04135911: A Prospective Study on The"Management of Hypertension in Young and Middle-aged Subjects in Enterprises Setting" |
|
|
| Suspended | N/A | 2000 | RoW | | Yan Li | Hypertension, Blood Pressure | 03/26 | 03/26 | | |
NCT05535400: Effects of Physical-Psychological Integrative Intervention on SCI Patient: a Pilot Randomized Controlled Trial |
|
|
| Completed | N/A | 72 | RoW | Physical-Psychological Integrative Intervention, Brief online didactic education | The Hong Kong Polytechnic University | Spinal Cord Injuries, Physical Inactivity, Depression, Chronic Pain | 12/22 | 07/23 | | |
| Recruiting | N/A | 60 | US | | Oregon Health and Science University, National Eye Institute (NEI) | Fuchs Dystrophy, Pseudophakic Bullous Keratopathy | 06/26 | 06/26 | | |
NCT05558657: Effect of Acupressure on Constipation in Community-dwelling Spinal Cord Injury Patients: a Randomized Controlled Trial |
|
|
| Completed | N/A | 80 | RoW | Home-based, acupressure combined with nursing education, Home-based, manual light touch of the abdomen combined with nursing education | The Hong Kong Polytechnic University | Spinal Cord Injuries, Traditional Chinese Medicine | 09/24 | 09/24 | | |
NCT05531058: The Impact of a Web-based Psychoeducation Programme With a Motivational AI Chatbot on Covid-19 Vaccine Hesitancy |
|
|
| Completed | N/A | 168 | RoW | AI-driven Vaccine Communicator, Self-learning of COVID-19 vaccine knowledge | The Hong Kong Polytechnic University | Vaccine Hesitancy, COVID-19 | 06/24 | 06/24 | | |
NCT01243931: Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy |
|
|
| Recruiting | N/A | 80 | US | OCT-guided laser phototherapeutic keratectomy, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789 | Oregon Health and Science University, National Eye Institute (NEI) | Corneal Opacity | 12/26 | 12/26 | | |
NCT02109471: Observational Study of Corneal Opacities in Adults |
|
|
| Recruiting | N/A | 150 | US | | Oregon Health and Science University, National Eye Institute (NEI) | Corneal Opacities (Scar and Stromal Dystrophy) | 12/25 | 12/25 | | |
| Recruiting | N/A | 75 | US | | Oregon Health and Science University | Uveitis | 12/25 | 12/25 | | |
NCT06306378: The Relationship Between Social Memory Disorders and Sleep Spindles in Children With Autism Spectrum Disorder |
|
|
| Recruiting | N/A | 60 | RoW | social memory levels and spindle levels | First Affiliated Hospital Xi'an Jiaotong University, Xi'an TCM Hospital of Encephalopathy | Autism Spectrum Disorder | 03/24 | 04/24 | | |
| Recruiting | N/A | 445 | US | Optical Coherence Tomography | Oregon Health and Science University | Keratoconus, Corneal Opacity, Corneal Dystrophy | 04/25 | 04/26 | | |
| Active, not recruiting | N/A | 60 | US | SKY Breath Intervention | University of California, San Francisco | Depression, Anxiety Disorders | 04/25 | 12/25 | | |
OCT IOL, NCT00532051: Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography |
|
|
| Recruiting | N/A | 690 | US | OCT measurements, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789 | Oregon Health and Science University, National Eye Institute (NEI) | Cataract | 07/26 | 07/26 | | |
NCT06686134: Comprehensive Clinical Evaluation Study of GLP-1RA |
|
|
| Recruiting | N/A | 492 | RoW | | LI YAN | T2DM | 12/25 | 07/26 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
TEAS/ASD, NCT06763237: Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder |
|
|
| Not yet recruiting | N/A | 42 | RoW | abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS), TEAS, Applied Behavior Analysis (ABA) therapy | First Affiliated Hospital Xi'an Jiaotong University, Xian Children's Hospital | Autism Spectrum Disorder, Autism in Children | 01/26 | 01/26 | | |
NCT06839378: Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei |
|
|
| Recruiting | N/A | 36 | RoW | intravenously inject with 5-FU (400 mg/m2) | Beijing Tsinghua Chang Gung Hospital, Tsinghua University | Pseudomyxoma Peritonei | 02/26 | 02/27 | | |
NCT05282095: Effect of HPV Integration on Prognosis of Young Women With CIN2 in China |
|
|
| Recruiting | N/A | 300 | RoW | Follow up | Fujian Maternity and Child Health Hospital | Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions | 12/25 | 05/26 | | |
| Recruiting | N/A | 300 | RoW | Diagnostic biomarker | Shixuan Wang | Uterine Sarcoma | 11/25 | 11/25 | | |
| Recruiting | N/A | 258 | US | | Oregon Health and Science University, National Eye Institute (NEI) | Keratoconus, Irregular; Contour of Cornea | 12/25 | 12/26 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Recruiting | N/A | 287 | Europe | Surgical treatment, Non-surgical treatment | Kolding Sygehus, Copenhagen University Hospital, Hvidovre, Zealand University Hospital, Oslo University Hospital, Helse Stavanger HF, Sahlgrenska University Hospital, Sweden, Uppsala University Hospital, Odense University Hospital, Hospital of Southern Jutland, Slagelse Hospital, Aalborg University Hospital, University Hospital, Umeå, Nordsjaellands Hospital, Holbaek Sygehus, Aarhus University Hospital, Copenhagen University Hospital, Herlev-Gentofte, University Hospital Bispebjerg and Frederiksberg, Viborg Regional Hospital, Karolinska University Hospital, Danderyd Hospital, Tampere University Hospital, Helsinki University Central Hospital | Fracture Humerus of Shaft | 12/25 | 07/31 | | |
NCT05858944: Home Blood Pressure Intervention in the Community Trial |
|
|
| Recruiting | N/A | 10000 | RoW | Intensive Home BP control, Home BP<125/75 mmHg, Standard Home BP control, Home BP<135/85 mmHg | Shanghai Institute of Hypertension | Home Blood Pressure | 12/29 | 06/30 | | |
| Recruiting | N/A | 450 | RoW | Healthy control specimen collection, Non-Borrmann IV patient specimen collection, Borrmann IV patient specimen collection | First Hospital of China Medical University, Liaoning Cancer Hospital & Institute, The Second Hospital of Shandong University, The General Hospital of Fushun Mining Bureau, The fourth People's Hospital of Changzhou, The First People's Hospital of Jingzhou | Stomach Neoplasms, Gut Microbiota, Metabolomics | 01/24 | 12/25 | | |
| Recruiting | N/A | 500 | RoW | YISAIPU® ( An etanercept biosimilar), a recombinant tumor necrosis factor receptor-Fc fusion protein, rhTNFR:Fc, csDMARDs | The First Affiliated Hospital of Xiamen University | Rheumatoid Arthritis | 06/25 | 12/25 | | |
| Fan, Jia |
NCT05660213: Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) |
|
|
| Not yet recruiting | 4 | 600 | NA | Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib, Sintilimab+Bevacizumab | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Unresectable Hepatocellular Carcinoma | 09/25 | 01/27 | | |
NCT04720716: A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC |
|
|
| Recruiting | 3 | 490 | RoW | IBI310, Sintilimab, Sorafenib | Innovent Biologics (Suzhou) Co. Ltd. | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT05320692: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 425 | RoW | TACE+Camrelizumab+Apatinib mesylate, TACE | Jiangsu HengRui Medicine Co., Ltd. | Hepatocellular Carcinoma | 07/26 | 07/26 | | |
| Active, not recruiting | 3 | 908 | Europe, Canada, Japan, US, RoW | Durvalumab, IMFINZI, Bevacizumab, AVASTIN, Placebo | AstraZeneca, AstraZeneca AB | Hepatocellular Carcinoma | 05/26 | 05/27 | | |
|
|
AK104-306, NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection |
|
|
| Not yet recruiting | 3 | 405 | RoW | AK104, placebo | Akeso | Hepatocellular Carcinoma | 01/25 | 11/26 | | |
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors |
|
|
| Recruiting | 2/3 | 178 | RoW | Neoadjuvant treatment | Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital | Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy | 12/25 | 12/26 | | |
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2/3 | 668 | RoW | QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab | Qilu Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 09/27 | 09/27 | | |
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2 | 128 | RoW | neoadjuvant treatment | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital | Cholangiocarcinoma, Intrahepatic | 08/21 | 08/23 | | |
ZSAB-TOP, NCT05023109: GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC |
|
|
| Active, not recruiting | 2 | 45 | RoW | GP+PD-1+Tight | Shanghai Zhongshan Hospital, Jining Medical University, Cancer Hospital of Guangxi Medical University | Biliary Tract Carcinoma | 01/23 | 12/24 | | |
NCT05190575: TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer |
|
|
| Completed | 2 | 8 | RoW | TST001 | Shanghai Zhongshan Hospital, Transcenta Holding Limited | Biliary Tract Neoplasms | 05/23 | 05/23 | | |
ZSAB-TransGOLP, NCT05156788: Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 40 | RoW | PD-1+Lenvatinib+GEMOX | Shanghai Zhongshan Hospital | Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib | 07/23 | 10/25 | | |
NCT04550624: Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Pembrolizumab Injection [Keytruda], Keytruda, Lenvatinib Mesylate, Lenvima | Shanghai Jiahui International Hospital, Shanghai Zhongshan Hospital | Advanced Biliary Tract Carcinoma | 12/24 | 12/25 | | |
SHR-A1811-212, NCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 65 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | 09/25 | 09/25 | | |
NCT06349980: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. |
|
|
| Recruiting | 2 | 117 | RoW | HLX53 (1000mg), HLX53 (2000mg), HLX10, Serplulimab, HLX04, Bevacizumab, Placebo | Shanghai Henlius Biotech | Carcinoma, Hepatocellular | 02/27 | 02/27 | | |
NCT06620848: A Study of HRS-4642 Monotherapy or in Combination with Adebrelimab in the Treatment of Advanced Biliary Tract Tumors. |
|
|
| Not yet recruiting | 2 | 49 | RoW | HRS-4642 monotherapy, HRS-4642 and adebrelimab combination therapy | Shanghai Zhongshan Hospital | Biliary Tract Cancer | 12/26 | 06/27 | | |
FAITH, NCT06031480: Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | 2 | 55 | RoW | Anlotinib and TQB2450 | Shanghai Zhongshan Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 10/25 | 12/25 | | |
NCT03867370: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma |
|
|
| Terminated | 1/2 | 40 | RoW | Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib | Shanghai Junshi Bioscience Co., Ltd. | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
